Role of ABC transporters in the chemoresistance of human gliomas

被引:57
作者
Decleves, Xavier
Amiel, Alexandra
Delattre, Jean-Yves
Scherrmann, Jean-Michel
机构
[1] INSERM, U705, CNRS, UMR 7157,Lab Neuropsychopharmacol,Fac Pharm, F-75006 Paris, France
[2] Hop Fernand Widal, INSERM, U705, F-75475 Paris 10, France
[3] Univ Paris 05, F-75270 Paris 06, France
[4] Univ Paris 07, F-75221 Paris 05, France
[5] CHU Pitie Salpetriere, Dept Neurooncol Mazarin, Paris, France
[6] Hop Hotel Dieu, Dept Pharm, Toxicol Lab, F-75181 Paris, France
关键词
ABC transporters; astrocytes; glioma; chemoresistance;
D O I
10.2174/156800906777723930
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several ATP-binding cassette (ABC) drug efflux transporters that are overexpressed by the endothelial or epithelial cells of these barriers. Second, resistance may involve the tumor cells themselves. Although ABC drug efflux transporters in tumor cells confer multidrug resistance (MDR) on several other solid tumors, their role in gliomas is unclear. This review focuses on astrocytes and summarizes the current state of knowledge about the expression, distribution and function of ABC transporters in normal and tumor astroglial cells. The recognition of anticancer drugs by ABC transporters in astroglial cells and their participation in the multidrug resistance phenotype of human gliomas is discussed.
引用
收藏
页码:433 / 445
页数:13
相关论文
共 119 条
[91]   Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas [J].
Okamoto, Y ;
Di Patre, PL ;
Burkhard, C ;
Horstmann, S ;
Jourde, B ;
Fahey, M ;
Schüler, D ;
Probst-Hensch, NM ;
Yasargil, MG ;
Yonekawa, Y ;
Lütolf, UM ;
Kleihues, P ;
Ohgaki, H .
ACTA NEUROPATHOLOGICA, 2004, 108 (01) :49-56
[92]  
Pardridge WM, 1997, J NEUROCHEM, V68, P1278
[93]   Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity [J].
Potschka, H ;
Fedrowitz, M ;
Löscher, W .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) :124-131
[94]  
Rasheed B K, 1999, Curr Opin Oncol, V11, P162
[95]   The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature [J].
Reavey-Cantwell, JF ;
Haroun, RI ;
Zahurak, M ;
Clatterbuck, RE ;
Parker, RJ ;
Mehta, R ;
Fruehauf, JP ;
Brem, H .
JOURNAL OF NEURO-ONCOLOGY, 2001, 55 (03) :195-204
[96]  
Regina A, 1998, J NEUROCHEM, V71, P705
[97]   Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo [J].
Rieger, L ;
Rieger, J ;
Winter, S ;
Streffer, J ;
Esser, P ;
Dichgans, J ;
Meyermann, R ;
Weller, M .
ACTA NEUROPATHOLOGICA, 2000, 99 (05) :555-562
[98]   Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures [J].
Ronaldson, PT ;
Bendayan, M ;
Gingras, D ;
Piquette-Miller, M ;
Bendayan, R .
JOURNAL OF NEUROCHEMISTRY, 2004, 89 (03) :788-800
[99]  
Savaraj N, 2003, INT J ONCOL, V23, P173
[100]  
Smits A, 2002, HISTOL HISTOPATHOL, V17, P253, DOI 10.14670/HH-17.253